van Hout, B A <br/><br/>
Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.  [electronic resource] 

 -  American heart journal  Apr 1998 
 - S98-106 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0002-8703 
<br/><br/><label>Standard No.: </label>10.1016/s0002-8703(98)70302-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Acute Disease<br/>Angioplasty, Balloon, Coronary<br/>Antibodies, Monoclonal--economics<br/>Coronary Disease--economics<br/>Cost-Benefit Analysis<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Follow-Up Studies<br/>Humans<br/>Immunoglobulin Fab Fragments--economics<br/>Infusions, Intravenous<br/>Platelet Aggregation Inhibitors--economics<br/>Prospective Studies<br/>Risk Factors<br/>Treatment Outcome<br/>United States